Background: Hilar cholangiocarcinoma has a low radical resection rate and a poor long-term survival rate. In recent years, its prognosis has been improved with advancement of preoperative diagnostic techniques and surgical techniques. The aim of this study was to evaluate the prognostic factors of hilar cholangiocarcinoma and the relations of surgical procedure to the prognosis of the carcinoma.

Methods: A retrospective cohort study was done in 198 patients with hilar cholangiocarcinoma (117 men and 81 women, aged from 27 to 81 years), who had been admitted to this hospital from December 1997 to December 2002. Their symptoms were jaundice (94.5%), pruritus (56.6%) and abdominal pain (33.8%). Bismuth-Corlette classification showed type I in 14 patients, type II in 19, type IIIa in 12, type IIIb in 15, type IV in 112, and unclassifiable type in 26. 144 patients underwent laparotomy and others received bile drainage endoscopically (including endoscopic retrograde biliary drainage (ERBD) or endoscopic metal biliary endoprosthesis (EMBE) in 21 patients, endoscopic nose-biliary drainage (ENBD) in 31 or percutaneous transhepatic cholangiodrainage in 2. 120 patients (83.3%) received tumor resection including radical resection in 59 patients (41.0%). Twenty-three patients underwent paunched biliary exploration and drainage.

Results: Cox's regression model analysis showed that occupation, preoperative total serum bilirubin level, operative procedure and postoperative adjuvant radiation were significantly related to postoperative survival rate in contrast to gender, age, choledocholithiasis, hepatitis, preoperative serum CA19-9 level, Bismuth-Corlette type, histopathologic grading and postoperative chemotherapy. The survival of patients in groups of biliary drainage, palliative resection and radical resection differed statistically and prolonged in a descending order. No statistical difference was found between ERBD or EMBE group and palliative resection group. So was between ERBD or EMBE group and biliary drainage group, or between ENBD group and biliary drainage group. The survival differed statistically between ERBD or EMBE group and ENBD group.

Conclusions: Operative procedure is the most important prognostic factor affecting the operative results of hilar cholangiocarcinoma. Radical resection is still the primary measure for a cure and long-term survival of the patients. For patients with irresectable hilar cholangiocarcinoma, no evidence has shown that the prognosis after treatment of ERBD or EMBE is poorer than that after laparotomy.

Download full-text PDF

Source

Publication Analysis

Top Keywords

hilar cholangiocarcinoma
24
radical resection
16
biliary drainage
16
erbd embe
16
embe group
12
patients
10
surgical procedure
8
procedure prognosis
8
long-term survival
8
survival rate
8

Similar Publications

Introduction: In an effort to treat patients with malignant hilar obstruction (MHO), both percutaneous trans-hepatic biliary stenting (PTBS) and endoscopic biliary stenting (EBS) strategies have been implemented in the clinic, but the relative advantages of these techniques remain to be clarified.

Aim: This meta-analysis was designed to compare the relative clinical efficacy of PTBS and EBS in MHO patients.Material and methods: Relevant studies were identified through searches of the PubMed, Web of science, and Wanfang databases, and pooled analyses of these studies were then performed.

View Article and Find Full Text PDF

Background: Recent research indicates a role of gut microbiota in development and progression of life-threatening diseases such as cancer. Carcinomas of the biliary ducts, the so-called cholangiocarcinomas, are known for their aggressive tumor biology, implying poor prognosis of affected patients. An impact of the gut microbiota on cholangiocarcinoma development and progression is plausible due to the enterohepatic circulation and is therefore the subject of scientific debate, however evidence is still lacking.

View Article and Find Full Text PDF

Current advance in comprehensive management of hilar cholangiocarcinoma and navigation in surgery: non-systematic reviews.

Int J Surg

December 2024

Hepatobiliary Surgery Department, National Cancer Center, National Clinical Research Center for Cancer, Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.

Hilar Cholangiocarcinoma (h-CCA) originates from the epithelial cells, which characters as longitudinal growth along the bile ducts and invasion of peripheral vascular nerves. Due to the tumours insidious progression and usually become advanced stage disease at presentation, patients' mortality could parallel incidence rates. For patients who are not amenable to resection, systemic therapy and palliative treatment become the way to go.

View Article and Find Full Text PDF

Background: Cholangiocarcinoma is a rare but highly fatal malignancy; numerous studies have demonstrated promising outcomes and survival rates associated with adjuvant photodynamic therapy (PDT) in the palliative treatment of cholangiocarcinoma.

Objective: To systematically evaluate the existing meta-analyses on PDT for cholangiocarcinoma, assessing evidence quality and strength while performing updated meta-analyses to refine survival outcomes.

Methods: PubMed, EMBASE, Cochrane Library, and Web of Science were systematically searched up to September 18, 2024, to identify meta-analyses and clinical studies on PDT in patients with cholangiocarcinoma.

View Article and Find Full Text PDF

Purpose: Perihilar cholangiocarcinoma (pCCA) is a rare malignancy requiring resection of extrahepatic bile ducts with or without hepatectomy. Prognostic models for post-operative outcomes in pCCA are unusable in pre-operative decision-making as most are based on post-operative variables. Additionally, no pre-operative models include futile laparotomy or benign hilar stenosis (BHS) as possible outcomes.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!